1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Pharmaceutical and Biotechnology Construction Sector Report – UK 2014-2018 Analysis

AMA Research are pleased to announce the publication of the 2nd Edition of the report 'Pharmaceutical and Biotechnology Construction Sector Report – UK 2014-2018 Analysis'. The report should be of particular interest to construction companies and their supply chains operating in the UK Life Sciences sector, and to suppliers of laboratory and allied products.

Key areas in the report:

• Review of the pharmaceutical, medical technology, medical and industrial biotechnology sectors – market size, key players and geographical areas of concentration.
• Overview of main manufacturing and R&D facilities in UK.
• Review of construction activity in the sector - key projects, pipelines, players etc.
• Analysis of Government resource and capital funding for science and research.

Areas of particular interest:

• Major contractors, consultants, architects and product suppliers involved in the pharmaceutical and biotechnology sectors.
• Capital Expenditure levels in the pharmaceutical/biotechnology market.
• Construction costs and issues in the design of pharmaceutical R&D/manufacturing facilities including legislation, regulatory requirements, containment and environmental issues, cleanroom and laboratory design.
• Profiles of top pharmaceutical/biotechnology companies operating in the UK - revenue, capital expenditure, key manufacturing & R&D facilities in UK, future strategy, expansion plans, forward pipelines etc.
• Forward pipeline of capital projects in the pharmaceutical sector between 2014-2018. Review of key projects together with announcements made by leading pharmaceutical companies and universities about future expansion and investment plans.
• Detailed analysis of pharmaceutical/biotech clusters and centres of excellence in the UK - the Oxford, Cambridge and London triangle houses the UK’s largest biomedical cluster, with over 350 pharma and biotech companies linked to universities and other organisations.
Leading pharmaceutical and biotechnology companies mentioned in the report include:
AstraZeneca, Abbott Laboratories, Abcam, ABS Laboratories, ACM Global Central Lab, Allergan, Bayer CropScience, Bells Healthcare, Calea (UK), Cancer Research Technology, Cantab Biopharmaceuticals, Carbogen Amcis, Cobra Biomanufacturing, Convergence Pharmaceuticals, Eli Lilly, GlaxoSmithKline, Huntingdon Life Sciences, Intercytex, Isis Innovation, Life Technologies, Lonza Biologics, MedImmune, Merck & Co, Mundipharma International, Norbrook Pharmaceuticals, Novartis UK, NuPharm Laboratories, Oxygen Healthcare, Pfizer, Pharmaserve Northwest, PsiOxus Therapeutics, Reading Scientific Services, Recipharm, Renovo, Roche, Sanofi Aventis, Sareum, Teva Pharmaceutical Industries, TPP Global Development, UCB Pharma, Unilever.

Leading construction companies and consultants mentioned in the report include:

ABB Group, AECOM, AMEC, Ardmac, Bassaire, BDP, Bilfinger SE, Cavendish Engineers, Clean Air Technologies, Clean Modules, Cleanroom Design & Construction, Cleanroom Solutions, ClearSphere, Enbloc Cleanrooms, Foster Wheeler, Jacobs Engineering, Kier Group, Laing O’Rourke, Lend Lease, M+W Group, Mach-Aire, Merit Merrell, Morgan Sindall, Nuvia, PM Group, Precision Cleanrooms, SDC, Shepherd Construction, Sheppard Robson, SISK Group, Validair, Wilson Mason.

Key areas covered in the report include:

OVERALL ‘ PHARMACEUTICAL’ MARKET
• Global Market - analysis of size by value 2009-16, historical trends and market characteristics.
• UK Pharmaceutical Market – by value 2011-16 – overview/ mix of key sectors – Pharmaceutical, Medical Technology, Medical Biotechnology, Industrial Biotechnology.
• Review of each key sector – key players, sector value, number of companies/staff, key locations, overview of development pipelines etc.

KEY PLAYERS
• Summary overview of Top 30+ companies in Pharmaceuticals / Biotechnology - major companies and geographic location of facilities in UK – Manufacturing, R&D, Packaging, Logistics.
• Geographic review – Oxford, Cambridge, London clusters. Other key regional areas - North West, Scotland, East England, South East etc – key players, future trends.
• R&D in UK – budgets, funding sources. Government Resource and Capital Funding for Science & Research 2011 – 2016. Research Councils (HEFCE, EPSRC, MRC etc). Key funding recipients. Overview of R&D – key players, locations, development plans.
• Top 20 companies in UK by R&D expenditure and by Drug Pipeline 2012/13.
• Top players – market shares. Company profiles - Key Operating & Financial Summary Data (Incl: Capital and R&D Expenditure, Locations, Pipelines, Future Strategy etc).
• Review of smaller players – pharmaceuticals / biotechnology – Capex, R&D, locations, developments etc.
• Universities – key links/collaborations with private sector, players (Top 20 with funding levels / sources). University/industry collaborations in the Pharmaceutical Sector – Partners, Funding, Project Areas etc.
• Spin-out companies - between 2006 and 2010 university spin-out companies floated on the stock market were worth around £3.5bn and over the over the past decade, university bioscience departments alone have generated over 200 spin-out companies – overview of key players.
• UK Science Parks - geographical spread, size / development plans, sectors, partners – Biocity, Liverpool, West of Scotland, York, Oxford, Cambridge etc.

CONSTRUCTION ACTIVITY
• Capital Expenditure – 2001-2012 by Value – trends, background, drivers etc.
• Science & Research Projects - Forward Construction Pipeline 2012-2017 – Schemes, Description, Funding Source, Status, Start/Completion Dates, Capex etc.
• Other development announcements – plans – medium/long term, new opportunities etc.
• Construction costs – laboratories, cleanrooms, key guidelines.
• Leading Contractors – specialist cleanroom players (construction, supply and services).
• Key consultants / contractors – Pharmaceuticals, Biotechnology - profiles of 20+ players – sector characteristics, major strengths and weaknesses, key sectors and capabilities.The UK is the 9th largest pharmaceutical market in the world, and the sector makes a greater contribution to the UK economy than any other industrial sector – worth around £29bn - and generating an annual trade surplus of almost £3bn. The Industry is particularly important in terms of its research and development (R&D) contribution and the pharmaceutical sector alone accounts for more UK-based business R&D than any other manufacturing sector – around £4.2bn is spent on pharmaceutical R&D in the UK, almost 25% of the total industrial R&D spend.

Growth rates are now significantly slower than in previous years, due to slowing R&D pipelines, dwindling R&D and healthcare budgets, rising costs, impending ‘patent cliffs’, increased regulatory controls and increased pricing pressures. In addition, significant public spending cuts especially in the health sector and tighter NHS spending is forecast to impact negatively on the pharmaceutical market. However, industry revenue is forecast to grow by around 2% between now and 2018.

The top 10 global pharmaceutical companies account for around £24bn or 47.3% of total UK sector turnover. Many of the top global pharmaceutical companies have a considerable manufacturing and research presence in the UK. 12 out of the top 20 global pharmaceutical companies account for a total of 55 UK sites.

Many of the UK’s biotech firms are located around Oxford, Cambridge and in Scotland. Known as ‘The Golden Triangle’ the centres of London, Cambridge, Oxford and Stevenage house the UK’s largest biomedical cluster in the UK. London and Cambridge are home to at least 60% of the UK’s life science industry base, with biotechnology R&D accounting for approximately 22% of the companies. Clusters of pharmaceutical companies are also found in areas close to universities. The North West, in particular, is home to ‘Big Pharma’, with several global pharmaceutical companies operating a facility in the region.

Capital expenditure by pharmaceutical companies in the UK has been in decline, with R&D capital expenditure falling by around £359m from £496m in 2002 to just £137m in 2012 and pharmaceutical manufacturing capital expenditure declining from a peak of nearly £1bn in 2001 to just £422m in 2012. For pharmaceutical manufacturing companies, the greatest barrier to capital investment in the UK over the last few years has been the lack of financial incentive to locate new manufacturing (or retain existing manufacturing plants) in the country.

However, the Government has also announced a forward pipeline of over £200m worth of capital projects in the pharmaceutical and biotechnology sectors between now and 2018. In addition to these confirmed capital projects, a number of expansion plans have been announced by leading pharmaceutical companies, which should be of interest to construction companies and their supply chains operating in the pharmaceutical sector and to suppliers of laboratory and allied products.

Increasing specialisation within the pharmaceutical industry has brought about varied opportunities for construction engineers and contractors to design and develop R&D facilities, pharmaceutical production processes, and assembly of drug delivery devices/systems, construction and maintenance of highly specialized production facilities, associated service/support facilities and continuous improvement of process operations.

Andrew Hartley, Director of AMA Research said “Current design and construction trends are moving away from ‘bespoke’ buildings to flexible and mobile laboratories and cleanrooms requiring less time to design and build and incorporating modern methods of construction. The demand for mobile or modular cleanrooms is increasing driven by industry cutbacks which have forced many pharmaceutical companies to rethink their business and manufacturing operations.”

While the performance of the global pharmaceutical market is now more positive in 2014 than in 2009, the fundamental problems of patent expiration and funding pressures still exist and will slow market increases to single-digit growth over the next few years and drive a shift towards generic drug equivalents. The pharmaceutical industry is facing a number of pressures which are set to limit sales, including price cuts and cost containment issues, growing regulatory pressure and major US and UK healthcare reforms. Cost-savings facilitated by mergers and acquisitions, geographic expansion into emerging markets and diversification into new areas such as consumer health are also set to drive the market going forward.

Table Of Contents

Pharmaceutical and Biotechnology Construction Sector Report - UK 2014-2018 Analysis
1. INTRODUCTION 6
2. SUMMARY AND FUTURE PROSPECTS 7
3. MARKET SIZE AND OVERVIEW 11
3.1 MARKET DEFINITION, SIZE AND VALUE 11
3.1.1 Global Pharmaceutical Market 11
3.1.2 UK Pharmaceutical Market 13
3.1.3 Medical Technology Sector 14
3.1.4 Medical Biotechnology Sector 15
3.1.5 Industrial Biotechnology Sector 16
3.1.6 Pharmaceutical Sector 16
3.2 PHARMACEUTICAL/BIOTECHNOLOGY CLUSTERS 20
3.2.1 Oxfordshire BioCluster 20
3.2.2 London, Cambridge and Stevenage BioClusters 20
3.2.3 Geographical Location of Pharmaceutical Manufacturing/RandD 21
3.3 VALUE OF THE PHARMACEUTICAL INDUSTRY TO THE UK ECONOMY 28
3.3.1 UK Trade in Pharmaceuticals 28
3.3.2 Sales of Pharmaceutical Drugs to the NHS 29
3.4 PHARMACEUTICAL RandD IN THE UK 31
3.4.1 Government Funding for Science RandD 31
3.4.2 Pharmaceutical Company Investment in RandD 34
3.4.3 RandD Pipeline 37
3.5 MARKET DRIVERS AND KEY ISSUES IN THE PHARMACEUTICAL INDUSTRY 38
3.5.1 Future of RandD in the UK 40
4. LEADING COMPANIES IN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS 43
4.1 OVERVIEW 43
4.2 PHARMACEUTICAL COMPANY LEAGUE TABLES 43
4.2.1 Global 43
4.2.2 UK 45
4.3 COMPANY PROFILES 46
4.3.1 Abbott Laboratories 46
4.3.2 AstraZeneca 47
4.3.3 GlaxoSmithKline (GSK) 49
4.3.4 Lilly 52
4.3.5 Merck and Co. Inc 53
4.3.6 Novartis 54
4.3.7 Pfizer 55
4.3.8 Roche 57
4.3.9 Sanofi-Aventis 58
4.3.10 Teva 60
4.4 OTHER PHARMACEUTICAL/BIOTECHNOLOGY COMPANIES 61
4.4.1 Biotechnology - Therapeutics/Diagnostics 61
4.4.2 Biotechnology RandD 62
4.4.3 Pharmaceutical 63
4.4.4 UK Science Parks 67
5. CONSTRUCTION ACTIVITY IN THE PHARMACHEM AND BIOTECHNOLOGY SECTOR 69
5.1 CAPITAL EXPENDITURE IN THE PHARMACEUTICAL SECTOR 69
5.2 PHARMACEUTICAL CONSTRUCTION PROJECT PIPELINE 70
5.3 CONSTRUCTION ISSUES IN THE PHARMACEUTICAL INDUSTRY 72
5.3.1 Construction Costs 72
5.3.2 Contamination/Control Issues 73
6. CONSTRUCTION CAPABILITY AND SUPPLY IN THE PHARMACEUTICAL and BIOTECHNOLOGY SECTOR 79
6.1 OVERVIEW 79
6.1.1 Specialist Cleanroom Construction, Supply and Services 79
6.1.2 Construction Consultants and Contractors - Pharmaceutical and Biotechnology Sectors 82
CHART 1 TURNOVER OF THE UK PHARMACEUTICAL MARKET (£BN) 2011-2018 7
CHART 2 GLOBAL PHARMACEUTICAL MARKET BY VALUE (£BN) 2009-2016 11
TABLE 3 TURNOVER AND NO. OF COMPANIES IN THE UK LIFE SCIENCES SECTOR - SHARE BY SECTOR (PHARMACEUTICAL, MEDICAL BIOTECHNOLOGY, MEDICAL TECHNOLOGY, INDUSTRIAL BIOTECHNOLOGY) - BY % AND VALUE (£BN) 2013 14
TABLE 4 PHARMACEUTICAL and BIOTECHNOLOGY SECTOR - MAJOR COMPANIES AND GEOGRAPHICAL LOCATION OF FACILITIES IN UK - MANUFACTURING, RandD, LOGISTICS, PACKAGING 18
CHART 5 UK PHARMACEUTICAL SECTOR- DISTRIBUTION OF UK MANUFACTURING AND RandD SITES 22
CHART 6 PHARMACEUTICAL TRADE IN THE UK - MARCH 2004 - MARCH 2014 (BY VALUE (£M) 28
CHART 7 SALES OF PRESCRIPTION MEDICINES TO THE NHS - 2004 - 2013 (£M) 30
TABLE 8 GOVERNMENT RESOURCE FUNDING FOR SCIENCE and RESEARCH 2010 - 2016 (£M) - BY FUNDING PROGRAMME 32
TABLE 9 GOVERNMENT CAPITAL FUNDING FOR SCIENCE and RESEARCH 2010 - 2016 (£M) - BY FUNDING PROGRAMME 34
TABLE 10 TOP 25 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY GLOBAL RandD SPEND IN 2012/13 (£M AND % OF TURNOVER) 36
TABLE 11 TOP 20 UK PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES BY DRUG PIPELINE SIZE IN 2014 37
TABLE 12 MAJOR DRUG PATENT EXPIRATIONS BY PRODUCT AND COMPANY 40
TABLE 13 TOP 20 GLOBAL PHARMACEUTICAL COMPANIES BY MARKET SHARE (%) 2013 44
TABLE 14 TOP 10 PHARMACEUTICAL COMPANIES' UK MARKET SHARE (%) 2013 46
TABLE 15 ABBOTT LABORATORIES - KEY OPERATING and FINANCIAL SUMMARY DATA (TURNOVER, CAPITAL EXPEND., RandD EXPEND., KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC) 47
TABLE 16 ASTRAZENECA - KEY OPERATING and FINANCIAL SUMMARY DATA (TURNOVER, CAPITAL EXPEND., RandD EXPEND., KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC) 49
TABLE 17 GLAXOSMITHKLINE - KEY OPERATING and FINANCIAL SUMMARY DATA 52
TABLE 18 LILLY - KEY OPERATING and FINANCIAL SUMMARY DATA 53
TABLE 19 MERCK and CO.- KEY OPERATING and FINANCIAL SUMMARY DATA 54
TABLE 20 NOVARTIS - KEY OPERATING and FINANCIAL SUMMARY DATA 55
TABLE 21 PFIZER - KEY OPERATING and FINANCIAL SUMMARY DATA 57
TABLE 22 ROCHE - KEY OPERATING and FINANCIAL SUMMARY DATA 58
TABLE 23 SANOFI AVENTIS - KEY OPERATING and FINANCIAL SUMMARY DATA 60
TABLE 24 TEVA - KEY OPERATING and FINANCIAL SUMMARY DATA 61
TABLE 25 OTHER TOP PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES - KEY OPERATING and FINANCIAL SUMMARY DATA - REVENUES, CAPITAL EXPENDITURE, RandD EXPENDITURE, KEY UK LOCATIONS, PRINCIPAL ACTIVITIES ETC 64
TABLE 26 UK SCIENCE PARKS - SIZE, GEOGRAPHICAL SPREAD, SECTORS, KEY PARTNERS 68
CHART 27 UK PHARMACEUTICAL INDUSTRY CAPITAL EXPENDITURE - RandD AND MANUFACTURING OPERATIONS (£M) - 2002-2012 69
TABLE 28 SCIENCE and RESEARCH PROJECTS - FORWARD CONSTRUCTION PIPELINE 2014-2018 71
TABLE 29 AIRBORNE PARTICULATE CLEANLINESS CLASSES FOR CLEANROOMS (BASED ON ISO 14644-1) 75

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.